Estudio de cohorte observacional prospectivo, multinacional, de pacientes con psoriasis crónica en placas de moderada a grave (VALUE).

CompletadoClinicalTrials.gov

ID: NCT03982394Tipo: OBSERVATIONALInicio: 1 de jul de 2019Fin estimado: 2 de sept de 2025

Resumen

Este estudio evaluará el uso de risankizumab en pacientes adultos con psoriasis crónica en placas de moderada a grave y comparará risankizumab con otros biológicos de uso frecuente.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's judgement at time of recruitment.
Participant starting any approved treatment for psoriasis and physician's decision must be reached prior to recruitment in the study.
Participant willing to continue with study documentation after cessation of therapy.

Criterios de exclusión

Unwillingness or inability to comply with study requirements.
Participation in an interventional clinical trial, concurrently or within the last 30 days. Participation in a post-market observational study (PMOS) or Registry is acceptable.

Ubicaciones

Emiliano Baccarini Priv Practice /ID# 218581

Lomas de Zamora, Buenos Aires, Argentina

Hospital Universitario Austral /ID# 217540

Pilar, Buenos Aires, Argentina

Stringa Dermatologia /ID# 218450

Ciudad Autonoma Buenos Aires, Buenos Aires F.D., Argentina